Delivery Order SPE2DB20D3103-SPE2DB25FQ2L4
- Not listed
- The Defense Logistics Agency awarded a $39,673.94 delivery order to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 ml vials on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is located in...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 22, 2025, for the supply of Ruxience 500 mg/50 ml vials, with a contract ceiling value of $5,381.40. The contract is a firm fixed-price delivery order with an ultimate completion date of July 23, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award was not set aside and was competitively awarded through open procurement processes, reflecting...
- The Defense Logistics Agency awarded a delivery order valued at $14,773.25 to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 mL vials. This competitively awarded, firm fixed-price delivery order was issued on August 21, 2025, with an ultimate completion date of August 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Ruxience is a biosimilar medication used in cancer treatment and other therapeutic applications, representing part of the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ruxience 500 mg/50 ml vials, a biosimilar monoclonal antibody used in cancer and autoimmune disease treatment. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $4,892.20 and an ultimate completion date of August 15, 2025. The contract involves no set-aside designation and utilizes AmerisourceBergen's place of performance in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ruxience 500 mg/50 mL vials, a biosimilar medication used in cancer treatment. This firm fixed-price delivery order, valued at $7,421.74, represents a non-set-aside competitive award with an ultimate completion date of August 13, 2025. The pharmaceutical products will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ruxience 500 mg/50 mL vials with a contract value of $2,935.32 and a completion date of August 5, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed-price pricing and represents a pharmaceutical supply transaction under the company's existing Indefinite Delivery Contract relationship with DLA. The place of performance is AmerisourceBergen's...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 ml vial medical products. The contract has a ceiling value of $9,786.84 and a completion date of August 13, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded this contract without a set-aside designation. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,913.72 firm fixed-price contract is for the delivery of the medication RUXIENCE 500 MG/50 ML VIAL 50ML. The contract has an ultimate completion date of July 3, 2025 and is not set aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, has been awarded a $1,204.48 firm fixed price delivery order by the Defense Logistics Agency Troop Support Medical to supply 100 mg/10 ml vials of the drug Ruxience. Performance will take place in Conshohocken, Pennsylvania over one day in late July 2023. The Defense Logistics Agency Troop Support Medical supports the medical readiness of the U.S. Armed Forces by procuring pharmaceuticals and other medical...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RUXIENCE 500 MG/50 ML VIAL 50ML. The contract has a ceiling value of $4,266.10 and is a firm-fixed-price delivery order, with a completion date of May 30, 2025. The contract is not set aside for any small business program. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ2L4Delivery Order
AmerisourceBergen Drug Corp received a $21,846.24 firm fixed-price delivery order from the Defense Logistics Agency (DLA) for 500 mg/50 mL vials of Ruxience, a biosimilar medication, with an ultimate completion date of September 11, 2025. This non-set-aside award was competitively issued and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical supply vehicle supporting military healthcare systems worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing critical medical supplies to federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The company's extensive federal portfolio demonstrates its capability to supply diverse pharmaceutical products ranging from specialty medications to generic drugs, vaccines, and medical devices across multiple therapeutic domains. This particular delivery order for Ruxience supports the company's ongoing role as a prime vendor within DLA's pharmaceutical supply chain, reinforcing its position as a key contractor for Department of Defense medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.8k | 9/10/25 |